SCHEMBL23330219

SCHEMBL23330219

CC(C)NCc1ccccc1-c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
HRH1 P35367 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
PTGS2 P35354 2/20 0.40
KCNH2 Q12809 2/20 0.39
KCNA5 P22460 1/20 0.39
TACR1 P25103 2/20 0.39
CD274 Q9NZQ7 1/20 0.39
MC4R P32245 3/20 0.39
LIPG Q9Y5X9 1/20 0.39
ALDH1A1 P00352 1/20 0.38
F10 P00742 1/20 0.38
TRPV3 Q8NET8 1/20 0.38
PTGS1 P23219 1/20 0.37
FFAR1 O14842 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31311016 0.86 HRH1 (0.53) BCHEACHEHRH1SLC6A4SLC6A3
SCHEMBL13164328 0.86 HRH1 (0.53) BCHEACHEHRH1SLC6A4SLC6A3
SCHEMBL23330016 0.85 BCHE (0.40) BCHEACHEHRH1KCNH2TACR1
SCHEMBL23330020 0.83 BCHE (0.41) BCHEACHEHRH1KCNH2TACR1
SCHEMBL23330221 0.83 KCNA5 (0.42) BCHEACHEHRH1KCNH2KCNA5
SCHEMBL22910539 0.81 ALDH1A1 (0.51) SLC6A4SLC6A3PTGS2KCNH2KCNA5
SCHEMBL23329976 0.81 CD274 (0.45) BCHEACHEHRH1CD274F10
SCHEMBL23330752 0.80 KCNA5 (0.47) BCHEACHEHRH1KCNH2KCNA5
SCHEMBL23330220 0.79 GPBAR1 (0.46) BCHEACHEHRH1ALDH1A1TRPV3
SCHEMBL13873005 0.77 KMT2A (0.44) SLC6A4SLC6A3PTGS2KCNH2KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210139477-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2021-05-13 US disclosed
US-20210130473-A1 TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139477-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF ALK, ALKBH5, ACVR1 BCHE 2478/4885ACHE 3192/4885HRH1 1637/4885
US-20210130473-A1 TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF TGFBR2, ASGR1, TGFBR1 BCHE 3676/4885ACHE 4690/4885HRH1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.